Generation and validation of Pomc-Cre Ppargfl/fl mice. To develop mice with selective ablation of PPARγ in POMC neurons, Cre transgenic mice, in which Cre recombinase is expressed specifically under the POMC promoter were crossed with Ppargfl/fl mice (Jackson Lab). In situ hybridization for Pparg mRNA combined with POMC immunocytochemistry showed colocalization in control mice (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI76220DS1), while no colocalization was observed in Pomc-Cre Ppargfl/fl mice (Supplemental Figure 1), confirming PPARγ deletion in the hypothalamic POMC neurons. Because POMC promoter also drives Cre recombinase expression in the pituitary, we examined the pituitary-adrenal axis. The expression levels of Pomc mRNA (1.00 ± 0.11 in male controls vs. 1.04 ± 0.12 in male Pomc-Cre Ppargfl/fl mice) as well as circulating corticosterone levels (46.6 ± 9.9 ng/ml in male controls vs. 47.1 ± 10.8 ng/ml in male Pomc-Cre Ppargfl/fl mice) were unaltered between the 2 genotypes. These data suggest that deletion of PPARγ in the pituitary does not affect the pituitary-adrenal axis.

Deletion of PPARγ in POMC neurons does not alter energy balance on standard chow diet. On a standard chow diet, no difference in body weight was found among female (Supplemental Figure 2A) and male (Supplemental Figure 3A) Pomc-Cre Ppargfl/fl, Pomc-Cre Ppargfl/+, and Ppargfl/fl (Cre negative defined as control) mice up to 16 weeks of age. The amount of adipose depot in both female (Supplemental Figure 2, B and C) and male (Supplemental Figure 3, B and C) Pomc-Cre Ppargfl/fl mice was not statistically significant compared with that of Pomc-Cre Ppargfl/+ and control mice. Leptin levels were also similar between Pomc-Cre Ppargfl/fl and control groups (1.15 ± 0.09 ng/ml in female Pomc-Cre Ppargfl/fl mice vs. 1.38 ± 0.05 ng/ml in controls; P > 0.05). EE and locomotor activity in both females and males were also similar between Pomc-Cre Ppargfl/fl and control mice (Supplemental Figure 2 and Supplemental Figure 3, D–H). No differences in thyroid hormones levels were found between these experimental groups (data not shown). When food intake was measured in a 24-hour period, female and male Pomc-Cre Ppargfl/fl mice showed no significant difference in feeding compared to that of control mice (females: 3.61 ± 0.16 g in Pomc-Cre Ppargfl/fl mice vs. 3.78 ± 0.15 g in controls; males: 3.86 ± 0.06 g in Pomc-Cre Ppargfl/fl mice vs. 4.02 ± 0.31 g in controls).

Loss of PPARγ in POMC neurons decreases peroxisome density and increases ROS levels in POMC neurons of HFD-exposed mice. Exposure to HFD significantly increases peroxisome density and decreases ROS levels in POMC neurons (7). To test the involvement of PPARγ, we analyzed peroxisome density and ROS levels in HFD-exposed Pomc-Cre Ppargfl/fl and control mice. A significant reduction in peroxisome density was observed in POMC neurons of Pomc-Cre Ppargfl/fl mice compared with in control mice (0.31 ± 0.05 peroxisomes/μm2 POMC cytosols in Pomc-Cre Ppargfl/fl mice vs. 0.58 ± 0.07 peroxisomes/μm2 POMC cytosols in control littermates, P < 0.05; Figure 1, A and B). POMC neurons of Pomc-Cre Ppargfl/fl mice also showed significantly greater ROS levels (6.26 ± 0.37 fluorescent particles in 10 μm2 cytosol) than those of control mice (4.23 ± 0.38 fluorescent particles in 10 μm2 cytosol; P < 0.05; Figure 1, C and D).

Figure 1 Lower peroxisome density and elevated ROS levels and neuronal activation in POMC neurons of Pomc-Cre Ppargfl/fl mice on HFD. (A) Electron micrographs showing representative sections of POMC perikarya in the arcuate nuclei of control and Pomc-Cre Ppargfl/fl mice. Red arrows point to peroxisomes. Images on bottom row are high-power magnification images of peroxisomes from the top row, respectively (numbers in images on the top row correspond with numbers in images on the bottom row). Scale bars: 500 nm. (B) Graph showing significantly lower peroxisome density in Pomc-Cre Ppargfl/fl animals compared with controls (n = 4 per group). (C) Representative confocal micrographs from control and Pomc-Cre Ppargfl/fl mice fed on HFD showing DHE (red) in POMC neurons (green). Scale bar: 20 μm. (D) Graph showing the density levels of DHE in POMC neurons of control (n = 4) and Pomc-Cre Ppargfl/fl mice (n = 4). (E) Representative confocal micrographs of double labeling for c-fos (red nuclei) and POMC (green cytoplasm) showing colocalization (white arrows) in the arcuate nucleus of the hypothalamus of a control and a Pomc-Cre Ppargfl/fl mouse fed on HFD. Scale bar: 50 μm. III, third ventricle. (F) Graph showing a significant increase in the percentage of c-fos/POMC double-labeled neurons in Pomc-Cre Ppargfl/fl mice compared with control littermates on HFD (n = 4 per group). Data in all graphs are shown as mean ± SEM. *P < 0.05.

Loss of PPARγ in POMC neurons induces increased POMC neuronal activity of HFD-exposed mice. Increased ROS levels in POMC neurons have been associated with increased POMC neuronal activity (7, 8). In agreement with these studies, a greater percentage of POMC neurons in Pomc-Cre Ppargfl/fl mice (19.20% ± 2.60%) showed c-fos staining in their nuclei compared with control mice (9.30% ± 1.81%; Figure 1, E and F).

Ablation of PPARγ in POMC neurons prevents hyperphagia and alters energy balance on HFD. The body weight of both female and male Pomc-Cre Pparg mice on HFD for 16 weeks was significantly lower than that of control mice. In female mice, a significant difference in body weight appeared as soon as 2 weeks of HFD feeding (Figure 2A). Female Pomc-Cre Pparg mice showed resistance to high-fat feeding, reaching an average body weight of 23.49 ± 0.99 g compared with that of control mice after 16 weeks of HFD exposure 27.44 ± 1.42 g (P = 0.03) (Figure 2A). On the other hand, the difference in body weight between males became evident later, at 9 weeks of HFD feeding (32.47 ± 0.48 g in controls and 30.22 ± 0.59 g in Pomc-Cre Ppargfl/fl mice), and after 16 weeks of HFD feeding, the average body weight of male Pomc-Cre Ppargfl/fl mice was 33.60 ± 1.98 g, while that for control mice was 39.62 ± 1.55 g (P < 0.05) (Figure 2B). Pomc-Cre Ppargfl/fl mice were also significantly lighter than Pomc-Cre Ppargfl/+ mice (Supplemental Figure 4) at 9 weeks of HFD, indicating that the effect on body weight between the controls (Ppargfl/fl-Cre negative) and the Pomc-Cre Ppargfl/fl mice was not due to the presence of the Pomc-Cre transgene. Consistent with the body weights, significant changes in body composition were observed (Figure 2, C–F). A decrease in fat mass (Figure 2, C and D) was observed in both female and male Pomc-Cre Ppargfl/fl mice compared with control littermates. The significant difference in fat mass in both males and females was reached at around 4 weeks of HFD exposure and persisted for the duration of the experiment (female fat mass at 16 weeks of HFD: 3.67 ± 0.37 g in Pomc-Cre Ppargfl/fl mice vs. 8.14 ± 1.45 g in control mice, Figure 2C; male fat mass at 16 weeks of HFD: 8.59± 1.25 g in Pomc-Cre Ppargfl/fl mice vs. 13.44± 1.13 g in control mice, P < 0.05, Figure 2D). Consistently, leptin levels were significantly (P = 0.009) lower in Pomc-Cre Ppargfl/fl mice (13.9 ± 1.6 ng/ml) compared with those in littermate controls (21.7 ± 1.2 ng/ml). No difference in lean mass was observed between groups (Figure 2, E and F).

Figure 2 Lower peroxisome density and elevated ROS levels and neuronal activation in POMC neurons of Pomc-Cre Ppargfl/fl mice on HFD is associated with a leaner phenotype. Analysis of (A and B) body weight (n = 9–14 per group), (C and D) fat mass (n = 9–14 per group), and (E and F) lean mass (n = 9–14 per group) showed that both (A, C, and E) female and (B, D, and F) male Pomc-Cre Ppargfl/fl mice were resistant to HFD compared with littermate controls. Data in all graphs are shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

To understand the cause of reduced body weight gain, we then measured food intake. Twenty-four–hour food intake analysis showed a slight but not significant decrease in food consumption in Pomc-Cre Ppargfl/fl animals compared with that in the controls on HFD (2.75 ± 0.21 g in female controls vs. 2.38 ± 0.15 g female Pomc-Cre Ppargfl/fl mice, P > 0.05, n = 5, Figure 3A; 2.87 ± 0.18 g in male controls vs. 2.68 ± 0.17 g in male Pomc-Cre Ppargfl/fl mice, P > 0.05, Figure 3B). However, when food intake was analyzed during the dark-and-light cycles, a significant difference in food intake was found during the dark phase (1.48 ± 0.17 g in female controls vs. 1.13 ± 0.09 g in female Pomc-Cre Ppargfl/fl mice, P < 0.05, Figure 3A; 1.40 ± 0.13 g in male Pomc-Cre Ppargfl/fl mice vs. 2.03 ± 0.22 g in male controls, P < 0.05, Figure 3B). No difference was observed during the light phase in both female mice (Figure 3A) and male mice (Figure 3B).

Figure 3 Pomc-Cre Ppargfl/fl mice on HFD have reduced feeding. Analysis of daily food intake in (A) female (n = 5–6 per group) and (B) male (n = 9–12 per group) mice on HFD shows that in both genders Pomc-Cre Ppargfl/fl mice ate less than control littermates. This difference in food intake was significant during the dark cycle in both female and male mice. Data in all graphs are shown as mean ± SEM. *P < 0.05 compared with controls.

We then measured EE and locomotor activity in male and female Pomc-Cre Ppargfl/fl mice and controls on HFD. Male Pomc-Cre Ppargfl/fl mice showed no difference in EE compared with that of controls when EE was normalized by lean mass (Figure 4A). However, when EE was analyzed using analysis of covariance (ANCOVA), a significant increase was observed in male Pomc-Cre Ppargfl/fl mice compared with that in controls (Figure 4B; 12.259 ± 0.136 kcal per day in Pomc-Cre Ppargfl/fl mice vs. 11.374 ± 0.123 kcal per day in controls, P < 0.05 both for body weight and genotype effects). Furthermore, EE was significantly increased during the light cycle (11.754 ± 0.211 kcal per day in Pomc-Cre Ppargfl/fl mice and 10.738 ± 0.190 kcal per day in controls, P < 0.05 both for body weight and genotype effects), but not during the dark cycle (12.482 ± 0.338 kcal per day in Pomc-Cre Ppargfl/fl mice and 12.023 ± 0.304 kcal per day in controls; P < 0.05 for body weight effect; P = 0.38 for genotype effect). Elevated levels of VO 2 (2,369.675 ± 24.604 ml per day in controls and 2,545.735 ± 27.360 ml per day in Pomc-Cre Ppargfl/fl mice, P < 0.05 both for body weight and genotype effects, Figure 4C) and VCO 2 (1,839.580 ± 29.576 ml per day in controls and 2,014.103 ± 32.888 ml per day in Pomc-Cre Ppargfl/fl mice, P < 0.05 both for body weight and genotype effects; Figure 4D) were also observed in Pomc-Cre Ppargfl/fl mice compared with control mice. No difference in the respiratory exchange rate (0.778 ± 0.010 in controls and 0.785 ± 0.013 in Pomc-Cre Ppargfl/fl mice) was observed (Figure 4E).

Figure 4 Pomc-Cre Ppargfl/fl mice on HFD have increased EE. (A and B) The results of EE analysis either after normalization by (A) lean mass or (B) ANCOVA analysis between male Pomc-Cre Ppargfl/fl and control mice (n = 5–6 per group). (C and D) The results of (C) VO 2 and (D) VCO 2 analysis in male Pomc-Cre Ppargfl/fl and control mice using ANCOVA (n = 5–6 per group). (E) No difference in respiratory quotient (RQ) was found between the 2 groups. (F) Increased locomotor activity during both dark and light cycles of male Pomc-Cre Ppargfl/fl mice compared with male controls. (G) Elevated BAT Ucp1 mRNA expression levels in male Pomc-Cre Ppargfl/fl mice (n = 7) compared with male controls (n = 4). Data in all graphs are shown as mean ± SEM. *P < 0.05 compared with controls.

The total locomotor activity of Pomc-Cre Ppargfl/fl mice on HFD was significantly higher than that of controls (56,217 ± 2,902 beam breaks per 48 hours in controls and 63,796 ± 3,680 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05; Figure 4F). This difference was due to an increased locomotor activity during both dark (41,379 ± 3,052 beam breaks per 48 hours in controls and 45,348 ± 2,342 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05; Figure 4F) and light phases (14,837 ± 1,140 beam breaks per 48 hours in controls and 18,448 ± 1,890 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05; Figure 4F).

To further analyze the increase in EE, we then assessed the expression of uncoupling protein 1 (UCP1) in the brown adipose tissues (BATs). A significant increase in Ucp1 mRNA was observed in Pomc-Cre Ppargfl/fl mice compared with their littermate controls (Figure 4G). However, no differences in thyroid hormone levels were observed between the 2 groups (free T3: 3.1 ± 0.8 ng/dl, n = 4 male controls vs. 3.6 ± 1.9 ng/dl, n = 6 male Pomc-Cre Ppargfl/fl mice; free T4: 1.9 ± 0.7 ng/dl, n = 4 male controls vs. 1.4 ± 0.3 ng/dl, n = 5 male Pomc-Cre Ppargfl/fl mice).

Female Pomc-Cre Ppargfl/fl mice showed increased EE compared with control mice on HFD both after normalization to lean mass (Supplemental Figure 5A) or after ANCOVA analysis (Supplemental Figure 5B; 11.279 ± 0.206 kcal per day in Pomc-Cre Ppargfl/fl mice vs. 10.594 ± 0.186 kcal per day in controls, P < 0.05 both for body weight and genotype effects). In contrast to the males, EE was significantly greater during the dark cycle in females (12.078 ± 0.202 kcal per day in Pomc-Cre Ppargfl/fl mice and 11.259 ± 0.0.183 kcal per day in controls, P < 0.05 for body weight and genotype effects) but not during the light cycle (10.499 ± 0.244 kcal per day in Pomc-Cre Ppargfl/fl mice and 9.946 ± 0.221 kcal per day in controls, P < 0.05 both for body weight effect; P = 0.149 for genotype effect). Elevated levels of VO 2 (2,199.616 ± 37.778 ml per day in controls and 2,338.401 ± 41.809 ml per day in Pomc-Cre Ppargfl/fl mice, P < 0.05 both for body weight and genotype effects; Supplemental Figure 5C) and VCO 2 (1,741.982 ± 34.032 ml per day in controls and 1,864.273 ± 37.663 ml per day in Pomc-Cre Ppargfl/fl mice, P < 0.05 for body weight effects, P = 0.052 for genotype effect; Supplemental Figure 5D) were also observed in Pomc-Cre Ppargfl/fl mice compared with control mice. No difference in the respiratory exchange rate (0.792 ± 0.005 in controls and 0.793 ± 0.004 in Pomc-Cre Ppargfl/fl mice, Supplemental Figure 5E) was observed. The total locomotor activity of Pomc-Cre Ppargfl/fl mice on HFD was significantly higher than that of controls (104,898 ± 8,851 beam breaks per 48 hours in controls and 157,906 ± 30,918 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05, Supplemental Figure 5F). This difference was due to an increased locomotor activity during both the dark phase (77,675 ± 5,783 beam breaks per 48 hours in controls and 102,227 ± 6031 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05, Supplemental Figure 5F) and the light phase (23,527 ± 1,271 beam breaks per 48 hours in controls and 35,361 ± 2,622 beam breaks per 48 hours in Pomc-Cre Ppargfl/fl mice, P < 0.05, Supplemental Figure 5F).

Insulin sensitivity in Pomc-Cre Ppargfl/fl mice. Analysis of glucose and insulin tolerance tests showed a greater glucose tolerance and insulin sensitivity of Pomc-Cre Ppargfl/fl mice compared with control littermates (Figure 5, A and B). No difference in insulin levels was found between the 2 experimental groups in fasted (0.31 ± 0.07 ng/ml in female Pomc-Cre Ppargfl/fl mice vs. 0.31 ± 0.02 ng/ml in control mice) or fed conditions (2.30 ± 0.57 ng/ml in female Pomc-Cre Ppargfl/fl mice vs. 2.19 ± 0.88 ng/ml in control mice). Liver analysis showed a decrease in the mRNA levels of hepatic gluconeogenesis enzymes, such as phosphoenolpyruvate carboxykinase (Pepck) (0.53 ± 0.06 in male Pomc-Cre Ppargfl/fl mice vs. 0.92 ± 0.15 in controls, P < 0.05, Figure 5C) and glucose-6-phosphatase (G6pase) (0.34 ± 0.07 in male Pomc-Cre Ppargfl/fl mice vs. 1.00 ± 0.25 in controls, P < 0.05, Figure 5D) in Pomc-Cre Ppargfl/fl mice compared with control littermates, indicating an increased hepatic insulin sensitivity in these mice.

Figure 5 Pomc-Cre Ppargfl/fl mice on HFD have improved glucose metabolism. (A) Increased glucose and (B) insulin tolerance in female Pomc-Cre Ppargfl/fl animals (n = 5) compared with controls (n = 8). (C and D) Graphs shown a significant decrease in the liver gluconeogenesis of Pomc-Cre Ppargfl/fl mice compared with matched controls, as shown by the liver mRNA levels of (C) Pepck (n = 4 per group) and (D) G6pase (n = 4 per group). Data in all graphs are shown as mean ± SEM. *P < 0.05 compared with controls.

To further analyze glucose metabolism in Pomc-Cre Ppargfl/fl mice, we performed hyperinsulinemic euglycemic clamp on mice on 9 weeks of HFD. To maintain blood glucose levels between 110 mg/dl and 130 mg/dl in both groups (Figure 6A), we needed to infuse approximately 2-fold glucose into Pomc-Cre Ppargfl/fl mice compared with control mice (the average glucose infusion rate between t = 75 minutes and t = 115 minutes was 8.6 ± 2.2 mg/kg/min in controls, n = 7, and 16.8 ± 2.8 mg/kg/min in Pomc-Cre Ppargfl/fl mice, n = 6, Figure 6B), suggesting that Pomc-Cre Ppargfl/fl mice had higher insulin sensitivity than control mice. Consistent with this, Pomc-Cre Ppargfl/fl mice had a significantly higher rate of disappearance (Rd), which represents whole-body glucose utilization during the clamp period, compared with control mice (16.6 ± 1.7 mg/kg/min in control mice and 21.6 ± 1.3 mg/kg/min in Pomc-Cre Ppargfl/fl mice, Figure 6C). Simultaneously, Pomc-Cre Ppargfl/fl mice also showed increased insulin-stimulated inhibition of endogenous glucose production, which mainly represents hepatic insulin sensitivity (40.2% ± 6.3% in controls and 68.2% ± 10.0% in Pomc-Cre Ppargfl/fl mice, Figure 6D). In agreement with the result of Rd, Pomc-Cre Ppargfl/fl mice had significantly greater 2-deoxy-d-glucose (2DG) uptake in epididymal white adipose tissue (EWAT) (Figure 6E; 3.4 ± 0.4 nmol/g/min in control mice and 5.9 ± 0.4 nmol/g/min in Pomc-Cre Ppargfl/fl mice), soleus, and the red portion of gastrocnemius muscle (Gastro-R) compared with that of control mice during the clamp period (soleus: 100.3 ± 18.4 nmol/g/min in controls and 188.5 ± 37.0 nmol/g/min in Pomc-Cre Ppargfl/fl mice; Gastro-R: 27.8 ± 4.0 nmol/g/min in controls and 58.6 ± 9.6 nmol/g/min in Pomc-Cre Ppargfl/fl mice; Figure 6F). 2DG uptake in both spleens and brains, which are not insulin-sensitive tissue, were not significantly different between groups (Figure 6G). These results suggest that deletion of PPARγ in POMC neurons improves glucose metabolism due to the enhancement of insulin sensitivity in EWAT, muscle, and liver during HFD feeding.

Figure 6 Pomc-Cre Ppargfl/fl mice on HFD have increased insulin sensitivity. (A) Glucose levels during the hyperinsulinemic-euglycemic clamp study in control (n = 7) and Pomc-Cre Ppargfl/fl mice (n = 6). (B) Graph showing a significant greater glucose infusion rate (GIR) during the hyperinsulemic-euglycemic clamp study in Pomc-Cre Ppargfl/fl mice compared with controls. (C) The increase in the rate of whole-body glucose disappearance (Rd) in Pomc-Cre Ppargfl/fl mice compared with controls. (D) Graph showing increased percentage of inhibition of hepatic glucose production in Pomc-Cre Ppargfl/fl mice compared with controls during the hyperinsulemic-euglycemic clamp study. (E and F) The increase in 2DG uptake in (E) EWAT and (F) muscles (soleus and Gastro-R) in Pomc-Cre Ppargfl/fl mice compared with controls. (G) No difference in 2DG uptake was observed in the spleens and in the brains of Pomc-Cre Ppargfl/fl and control mice. Data in all graphs are expressed as the mean ± SEM. *P < 0.05; **P < 0.01.

PPARγ deletion in POMC neurons increases leptin sensitivity on HFD. To test leptin sensitivity, HFD-fed Pomc-Cre Ppargfl/fl and control mice were i.p. injected with leptin twice a day for 3 days, with a dose of leptin of 1.5 μg/g body weight. Compared with controls, Pomc-Cre Ppargfl/fl mice showed a significant reduction in food intake (day 3: –30% ± 6.59% reduction of food intake) compared with control littermates (day 3: –12.42% ± 2.65% reduction food intake, P < 0.05 vs. WT mice, Figure 7A). Pomc-Cre Ppargfl/fl mice also showed a significant reduction in body weight gain (day 3: 1.80% ± 0.72% in control vs. 5.41% ± 0.60% of Pomc-Cre Ppargfl/fl mice; P < 0.05 vs. control mice, Figure 7B).

Figure 7 Pomc-Cre Ppargfl/fl mice on HFD are sensitive to leptin. (A and B) Daily food intake and body weight of control and Pomc-Cre Ppargfl/fl mice (n = 4–6 per group) treated with leptin for 3 days on HFD for 12 weeks. Arrows indicate leptin administration. (C) Representative confocal micrographs of p-STAT3 (red) and POMC (green) double immunolabeled hypothalamic sections (white arrows) from leptin-treated control and Pomc-Cre Ppargfl/fl mice. Scale bar: 50 μm. (D) A higher percentage of POMC neurons with p-STAT3–labeled nuclei in the arcuate nuclei of Pomc-Cre Ppargfl/fl mice was detected compared with controls (n = 4–6 per group). (E) Representative confocal photomicrographs of control and Pomc-Cre Ppargfl/fl mice double immunostained (white arrows) for POMC (green) and c-fos (red). Scale bar: 50 μm. (F) Pomc-Cre Ppargfl/fl mice showed an increased level of c-fos/POMC immunostaining in the arcuate nucleus of the hypothalamus compared with controls (n = 4–6 per group). (G) Electron micrographs showing representative sections of POMC perikarya in the arcuate nuclei from control and Pomc-Cre Ppargfl/fl mice. Red asterisks show mitochondria in close association with ER. Scale bar: 1 μm. (H) Quantification of mitochondria-ER interaction revealed higher numbers of mitochondria-ER contacts in POMC neurons of Pomc-Cre Ppargfl/fl animals compared with control animals (n = 4 per group). Data in all graphs are expressed as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

To assess activation of the leptin-associated signal pathway, p-STAT3 immunoreactivity was analyzed after leptin treatment. After i.p. leptin injection, p-STAT3 expression in POMC neurons was significantly increased in Pomc-Cre Ppargfl/fl mice (45.63% ± 4.91%) compared with control mice on HFD (19.42% ± 4.04%, Figure 7, C and D). Similarly, c-fos immunostaining in POMC neurons was significantly higher in Pomc-Cre Ppargfl/fl mice (24.28% ± 3.90%) compared with that in control littermates (6.00% ± 2.09%, Figure 7, E and F).

Endoplasmic reticulum (ER) stress plays a key role in the development of obesity and leptin resistance (9, 10). Recently, close interaction between mitochondria and ER has been shown to play an important role in the onset of obesity and leptin resistance (11). Analysis of mitochondria-ER interaction in our study showed that the number of mitochondria-ER contacts in POMC neurons of Pomc-Cre Ppargfl/fl mice was significantly greater (53.05 ± 2.71) than those in POMC neurons of control mice (23.35 ± 3.61, P < 0.001, Figure 7, G and H)

PPARγ in POMC neurons mediates rosiglitazone and GW9662 effects on food intake. To assess whether the effects of PPARγ activation or inhibition are mediated by PPARγ expression in POMC neurons, we then assessed food intake of Pomc-Cre Ppargfl/fl and control mice treated i.p. with either rosiglitazone, a PPARγ agonist, or GW9662, a PPARγ antagonist, for 5 days.

Rosiglitazone administration to lean control mice exposed to HFD caused a significant increase in food intake (23.3% ± 3.03%) and body weight gain (4.47% ± 0.63%) compared with Pomc-Cre Ppargfl/fl mice (–0.2% ± 8.4% food intake and 1.08% ± 1.16% body weight, P < 0.05, Figure 8, A and B, respectively).

Figure 8 Peripheral administration of either rosiglitazone or GW9662 fails to affect food intake in Pomc-Cre Ppargfl/fl mice. (A) The effect of rosiglitazone administration on the food intake of lean control mice exposed to HFD (n = 5–6 per group). The percentage change in food intake before (vehicle treated) and after rosiglitazone treatment shows that rosiglitazone did not significantly alter food intake in Pomc-Cre Ppargfl/fl mice. (B) The effect of rosiglitazone administration on the body weight of lean control mice exposed to HFD. The percentage change in body weight before (vehicle treated) and after rosiglitazone treatment shows that rosiglitazone did not significantly alter body weight in Pomc-Cre Ppargfl/fl mice. (C) The effect of GW9662 administration on HFD-exposed mice for 16 weeks (n = 6 per group). The percentage change in food intake before (vehicle treated) and after GW9662 treatment shows that GW9662 failed to significantly decrease food intake in Pomc-Cre Ppargfl/fl mice. (D) The effect of GW9662 administration on the body weight of HFD-exposed mice for 16 weeks. The percentage change in body weight before (vehicle treated) and after GW9662 treatment shows that GW9662 failed to significantly decrease body weight in Pomc-Cre Ppargfl/fl mice. Data in the graphs are expressed as the mean ± SEM. *P < 0.05; **P < 0.01.

Similarly, GW9662 administration to HFD-exposed mice for 16 weeks significantly reduced food intake (–11.87% ± 3.86%) and body weight change (–4.95% ± 1.16%) in control mice compared with Pomc-Cre Ppargfl/fl mice (1.42% ± 4.22% food intake and –0.41% ± 0.28% body weight, P < 0.05, Figure 8, C and D, respectively).